Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 19/20 | 0.57 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13915595 | 0.91 | EGFR (0.53) | CSF1RNUDT1EGFRERBB2 | |
| SCHEMBL13915598 | 0.86 | MAPT (0.51) | CSF1R | |
| SCHEMBL2749299 | 0.86 | CSF1R (0.64) | CSF1RNUDT1 | |
| SCHEMBL5929634 | 0.83 | CSF1R (0.57) | CSF1RNUDT1EGFR | |
| SCHEMBL5929704 | 0.83 | CSF1R (0.57) | CSF1RNUDT1EGFR | |
| SCHEMBL13915594 | 0.82 | SRC (0.54) | EGFRERBB2 | |
| SCHEMBL2724559 | 0.80 | CSF1R (0.58) | CSF1RNUDT1 | |
| SCHEMBL5650362 | 0.78 | ENPP1 (0.55) | CSF1REGFR | |
| SCHEMBL12431119 | 0.78 | ENPP1 (0.55) | CSF1REGFR | |
| SCHEMBL5929884 | 0.78 | CSF1R (0.56) | CSF1RNUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504416-B2 | 4-substituted quinolines as antitumor agents | ASTRAZENECA AB (SE) | 2009-03-17 | — | — | US | disclosed |
| US-7402583-B2 | Substituted quinolines as antitumor agents | ASTRZENCA AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-20080027054-A1 | 4-Substituted quinolines as antitumor agents | ASTRAZENECA AB | 2008-01-31 | — | — | US | disclosed |
| US-20070021407-A1 | Substituted quinolines as antitumor agents | ASTRAZENECA | 2007-01-25 | — | — | US | disclosed |
| US-20070021407-A1 | Substituted quinolines as antitumor agents | ASTRAZENECA | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021407-A1 | Substituted quinolines as antitumor agents | NR1H3, NR1H2, NR0B1 | CSF1R 182/4885NUDT1 1579/4885EGFR 260/4885 |
| US-20080027054-A1 | 4-Substituted quinolines as antitumor agents | CCNY, TPD52L2, H1-10 | CSF1R 991/4885NUDT1 1249/4885EGFR 947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.